Ertugliflozin yields improved metabolic profile in T2D with high BMI

  • Heymsfield SB & al.
  • Obesity (Silver Spring)
  • 1 Apr 2020

  • curated by Miriam Tucker
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with type 2 diabetes (T2D) and overweight/obesity, ertugliflozin reduced HbA1c, body weight, and systolic BP (SBP).

Why this matters

  • Approximately 90% of patients with T2D have overweight/obesity.

Study design

  • Pooled 26-week data from 3 placebo-controlled, randomized, phase 3 studies included 1377 individuals with T2D and baseline BMI ≥25 (25 to
  • Funding: Merck & Co., Inc., Kenilworth, NJ, USA.

Key results

  • Least-squares mean change (95% CI) from baseline in HbA1c:
    • Placebo: 0.1% (0.0%-0.1%);
    • Ertugliflozin 5 mg: −0.8% (−0.8% to −0.7%); and 
    • Ertugliflozin 15 mg: −0.9% (−1.0% to −0.8%).
  • Proportions achieving HbA1c
  • Placebo: 15.9%;
  • Ertugliflozin 5 mg: 32.3%; and
  • Ertugliflozin 15 mg: 40.7%.
  • Body-weight reduction from baseline (kg; 95% CIs):
    • Placebo: −1.2 (−1.5 to −0.9); 
    • Ertugliflozin 5 mg: −3.1 (−3.4 to −2.8); 
    • Ertugliflozin 15 mg: −3.2 (−3.5 to −2.9).
  • SBP reductions (mmHg; 95% CIs):
    • Placebo: −0.8 (−1.8 to 0.2); 
    • Ertugliflozin 5 mg: −4.6 (−5.6 to −3.6); and
    • Ertugliflozin 15 mg: −4.6 (−5.6 to −3.6).
  • Patterns were similar across BMI subgroups. 
  • Adverse events were similar across groups, except for more genital mycotic infections with ertugliflozin, particularly among women.
  • Limitations

    • Post hoc.
    • Short-term.
    • Small subgroup numbers.